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Abstract 
Background: Viral vector-based therapeutic gene therapy is a potent strategy to enhance the intrinsic 
reparative abilities of human orthopaedic tissues. However, clinical application of viral gene transfer remains 
hindered by detrimental responses in the host against such vectors (immunogenic responses, vector 
dissemination to nontarget locations). Combining viral gene therapy techniques with tissue engineering 
procedures may offer strong tools to improve the current systems for applications in vivo. 
Methods: The goal of this work is to provide an overview of the most recent systems exploiting biomaterial 
technologies and therapeutic viral gene transfer in human orthopaedic regenerative medicine. 
Results: Integration of tissue engineering platforms with viral gene vectors is an active area of research in 
orthopaedics as a means to overcome the obstacles precluding effective viral gene therapy. 
Conclusions: In light of promising preclinical data that may rapidly expand in a close future, biomaterial-
guided viral gene therapy has a strong potential for translation in the field of human orthopaedic regenerative 
medicine. 
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Introduction 
Regeneration of injured orthopaedic tissues (articular cartilage, bone, meniscus, tendons, 
ligaments) remains problematic in light of their insufficient or deficient capacity to regenerate at 
both structural and biomechanical levels. 
 
In absence of vascularization, the articular cartilage that allows for load transmission and mobility 
of the joints has a poor ability for self-repair and lesions resulting from trauma or generalized 
osteoarthritis (OA) [1,2,3] tend to further deteriorate if left untreated, leading to the production of 
a poor fibrocartilaginous repair tissue made of type-I collagen instead of a hyaline cartilage 
naturally composed of type-II collagen and proteoglycans, even following surgical treatment 
(microfacture, autologous chondrocyte implantation—ACI, administration of mesenchymal stem 
cells—MSCs, replacement surgery) [4, 5]. 
 
In contrast, the hierarchical, vascularized bone with type-I collagen fibers and nanohydroxyapatite 
matrix for skeletal support and mobility has an intrinsic ability to heal. Still, such potential might 
be constrained when the lesions (or fractures) are too large to fully regenerate [6, 7], even 
following autografting procedures that are hampered by limited graft availability, donor site 
morbidity, and graft integration [8]. 
 
Injuries to the meniscus, a tissue with loadbearing and stabilization functions that is essentially 
made of type-I collagen and vascularized only in its periphery (10–30% of the structure), poorly 
heal in the prevalent, central (avascular) region like after trauma or during OA progression [9]. 
Approaches to treat meniscal lesions include meniscal reconstruction, replacement (allografts, 
substitutes), and cell application but they do not always restore the meniscus in its full mechanical 
integrity [10]. 
 
Connective tendons that transmit elastic forces between bone and muscles for locomotion and 
ligaments between bones for stability, both composed of type-I collagen, may be submitted to 
injury (tears, ruptures, tendinopathy) that poorly heal, forming a scar tissue of lesser quality or 
with adhesions [11, 12] and none of the current treatments (suture, grafts, synthetic prostheses) 
promote a long-term reconstruction of functional tissues. 
 
In this regard, gene therapy [13] may provide powerful, clinically adapted tools to express 
therapeutic candidate sequences in orthopaedic lesions in a temporarily and spatially defined 
manner relative to the direct administration of recombinant agents that generally display very short 
pharmacological half-lives (minutes to hours) [14,15,16,17,18,19,20]. While nonviral vectors have 
been long manipulated for human gene therapy [21, 22], viral vectors became the focus of 
orthopaedic regenerative medicine due to their natural entry pathway in target cells and to their 
overall higher gene transfer efficiencies [19, 23]. 
Viral gene transfer for orthopaedic tissue repair: classical approaches 
Viral vectors 
A variety of viral vectors have been employed to treat orthopaedic lesions including gene vehicles 
based on adenoviruses [24], herpes simplex viruses (HSV) [25], retro/lentiviruses [26, 27], and on 
the adeno-associated virus (AAV) [28,29,30]. Episomal adenoviral and HSV vectors are highly 
efficient to modify dividing and nondividing cells (~ 100% transduction efficiencies) but only over 
limited periods of time (some days to 1–2 weeks) while provoking detrimental host immune 
responses [31]. Integrative retro/lentiviral vectors persist in the host genome but transduce cells at 
lower efficiencies (< 20% unless manipulated by cell selection) and having a risk for insertional 
mutagenesis and tumorigenesis [32]. In addition, retroviral vectors can target only dividing cells 
while lentiviral vectors may carry human immunodeficiency virus (HIV)-derived genetic material. 
Gutless rAAV vectors can optimally and durably target dividing and nondividing cells (~ 100% 
transduction efficiencies for months to years) [33] as predominant stable episomes, even in the 
presence of a dense extracellular matrix due to their small size (~ 20 nm) [34]. The absence of viral 
coding sequences in the rAAV genome make these vectors much less immunogenic and toxic than 
adenoviral and HSV vectors and a possible cause-to-effect of rAAV-associated genotoxicity 
(insertional mutagenesis) [35] has been excluded to date when using a gutless vector [36]. 
 
According to the gene delivery efficiency of a vector, direct in vivo vector application (adenoviral, 
HSV, or rAAV vectors) or indirect ex vivo cell-associated gene transfer (retro/lentiviral vectors) 
may be favorized for orthopaedic applications in a recipient. 
 
Classical viral gene therapy for orthopaedic tissue repair: direct gene transfer (Table 1) 
Direct gene administration has been documented for the treatment of cartilage defects using 
adenoviral [37] and rAAV vectors [38,39,40,41,42] to deliver the insulin-like growth factor I 
(IGF-I) [41], transforming growth factor beta (TGF-β) [42], basic fibroblast growth factor (FGF-2) 
[38, 39], interleukin 10 (IL-10) with an IL-1 receptor antagonist (IL-1Ra) [37], and the sex-
determining region Y-type high mobility group box 9 transcription factor (SOX9) [40], leading for 
instance to enhanced cartilage repair for 16 weeks in rabbits [38, 40]. 
Table 1 Direct gene transfer in orthopaedic regenerative medicine 
Applications Vectors Genes Targets References 
     
Cartilage repair Adenoviral 
vectors 
IL-10 + IL-1Ra Horse CD (16 weeks) [37] 
  rAAV vectors FGF-2, SOX9, 
IGF-I, TGF-β 
Rabbit OCD (16 weeks) [38,39,40,41,42] 
Bone healing Adenoviral 
vectors 
BMP-2, VEGF Rabbit femoral fracture (16 
weeks) 
[43,44,45,46,47,48,49] 




Rat femoral fracture (28 days) [50,51,52] 





rAAV vectors FGF-2, VEGF Human ACL and chicken 
flexor tendon injuries (6 
weeks) 
[55,56,57] 
     
 
rAAV, recombinant adeno-associated virus vector; IL-10, interleukin 10; ; IL-1Ra, interleukin 1 receptor antagonist; FGF-
2, basic fibroblast growth factor; SOX9, sex determining region Y-box 9; IGF-I, insulin-like growth factor I; TGF-β, 
transforming growth factor beta; BMP, bone morphogenetic protein; VEGF, vascular endothelial growth factor; LMP-1, 
LIM mineralization protein 1; COX-2, cyclooxygenase 2; CD, chondral defect; OCD, osteochondral defect; ACL, anterior 
cruciate ligament 
  
Direct gene therapy has been also attempted for bone healing using adenoviral 
[43,44,45,46,47,48,49] and retro/lentiviral vectors [50,51,52] to deliver the bone morphogenetic 
proteins (BMP-2, -4) [43, 45,46,47,48,49,50], vascular endothelial growth factor (VEGF) [44], 
LIM mineralization protein-1 (LMP-1) [52], and cyclooxygenase-2 (COX-2) [51] in bone defects 
or fractures, leading for instance to improved bone repair for 16 weeks in rabbits [45]. 
 
Direct administration of therapeutic genes via rAAV-mediated gene transfer has also been 
performed in the meniscus [53, 54] and tendons/ligaments [55,56,57] to promote the healing of 
human experimental meniscal lesions in situ upon overexpression of FGF-2 [53] and TGF-β [54] 
for 15 days [54] and the repair of human experimental anterior cruciate ligament (ACL) lesions in 
situ using FGF-2 [55] or of injured chicken flexor tendons with FGF-2 [56, 57] or VEGF [57] for 
6 weeks [57]. 
Classical viral gene therapy for orthopaedic tissue repair: indirect gene transfer (Table 2) 
Indirect gene transfer approaches in cartilage lesions include the administration of MSCs (bone 
marrow, perichondrium/periosteum, muscle, adipose tissue, tendons) [58,59,60,61,62,63,64,65], 
articular chondrocytes [66,67,68], bone marrow aspirates [69, 70], or tissue grafts (muscle, fat) 
[71, 72] modified by adenoviral [58, 60, 66, 67, 69,70,71,72], retro/lentiviral [59, 62,63,64,65], 
and rAAV vectors [61, 68] to deliver IGF-I [58, 67, 68], BMPs (BMP-2, -4, -7) 
[59, 60, 63, 66, 70,71,72], TGF-β [61, 69], sFlt-1 (a VEGF antagonist) [62, 63], the SOX trio 
(SOX-5, -6, -9) [65], the zinc-finger protein 145 (ZNF145) [64], and indian hedgehog (IHH) [70], 
leading for instance to enhanced cartilage repair for 8 months in horses [67, 68]. 
  
Table 2 Indirect gene transfer in orthopaedic regenerative medicine 
Applications Cells, tissues Vectors Genes Targets References 





















BMP-7, IGF-I Horse CD (8 months) [66, 67] 
  rAAV vectors IGF-I Horse CD (8 weeks) [68] 




Sheep/rabbit CD (24 and 
13 weeks) 
[69, 70] 




BMP-2 Rabbit OCD (13 weeks) [71, 72] 
Bone healing MSCs rAAV vectors BMP-2, VEGF Mouse tibial defect (16 
weeks) 
[74] 
  Adenoviral 
vectors 
BMP-2 Rat femoral defect (8 
weeks) 
[73] 








  rAAV vectors VEGF, RANKL, 
caAlk2 
Mouse femoral defect (6 
weeks) 





TGF-β Rabbit Achilles tendon 
injury (8 weeks) 
[82] 






Rat Achilles tendon and 
horse FGST injuries (8 
weeks) 
[84,85,86] 
  Lentiviral 
vectors 
Scx Rat patellar tendon injury 
(2 weeks) 
[88] 
  rAAV vectors GDF-5 Mouse FDLT injury (3 
weeks) 
[83, 87] 
      
 
MSCs, human mesenchymal stem cells; rAAV, recombinant adeno-associated virus vector; IGF-I, insulin-like growth 
factor I; BMP, bone morphogenetic protein; sFlt-1, a VEGF antagonist; ZNF145, zinc-finger protein 145; SOX trio, sex 
determining region Y-boxes 5, 6, and 9; TGF-β, transforming growth factor beta; IHH, indian hedgehog; VEGF, vascular 
endothelial growth factor; RANKL, receptor activator of nuclear factor κB ligand; caAlk2, constitutively active form of the 
ALK2 receptor; Scx, scleraxis; GDF-5, growth and differentiation factor 5; CD, chondral defect; OCD, osteochondral 
defect; OA, osteoarthritis; FGST, flexor digitorum superficialis tendon; FDL: flexor digitorum longus tendon 
Indirect gene therapy for bone healing has been achieved by applying MSCs (bone marrow) with 
or without extra bone matrix [73, 74] and tissue grafts (bone, muscle, fat) 
[71, 75,76,77,78,79,80,81] modified by adenoviral [71, 73, 77, 79,80,81] and rAAV vectors 
[74,75,76, 78] to produce BMPs (BMP-2, -7) [71, 73, 74, 77,78,79,80,81], VEGF [75], the 
receptor activator of nuclear factor κB ligand (RANKL) [75], and the constitutively active form of 
the ALK2 receptor (caAlk2) [76], promoting for instance bone healing for 16 weeks in mice [74]. 
Indirect modification of MSCs (bone marrow) [82] and tissue grafts (tendon, muscle) 
[83,84,85,86,87,88] via adenoviral [82, 84,85,86], lentiviral [88], and rAAV vectors [83, 87] for 
implantation in experimental lesions has also been tested to enhance tendon healing upon gene 
transfer of the growth and differentiation factor 5 (GDF-5) [83, 87], IGF-I [85], TGF-β [82, 86], 
BMPs (BMP-12) [84], and scleraxis (Scx) [88] for 8 weeks in rabbits [82] and horses [85]. 
  
Classical gene transfer: limitations 
A large number of issues remain regarding the effective use of classical gene transfer strategies. 
While direct gene transfer is a simple procedure, it may lead to vector dissemination to non-target 
organs and clearance from the body [89,90,91,92]. On the other side, the manipulation of 
genetically modified cells in indirect gene transfer protocols may allow to control the gene vector 
cargo and promote cell repopulation in sited of lesions, although being dependent on invasive 
methods of extraction [93]. Another critical problem is the pre-existing immunity against viral 
vectors (neutralizing antibodies and cellular immune responses against the viral capsid proteins) 
[94,95,96,97,98]. Finally, physiological barriers may further impair gene transfer like the presence 
of patient-associated factors (presence of inhibiting anticoagulants) [99] or viral vector-specific 
features (rate-limiting steps of viral genome processing for effective transgene expression) 
[100, 101]. 
Viral gene therapy and tissue engineering for orthopaedic tissue repair 
Concepts 
A novel, highly promising strategy to overcome such hurdles is to combine the use of viral gene 
transfer with existing tissue engineering approaches based on the manipulation of clinically 
relevant biocompatible and biodegradable materials (hydrogel, solid, and hybrid scaffolds) that 
can mimic the natural properties of orthopaedic tissues, integrating well with the surrounding 
tissue while providing a supportive, scaffolding environment for cell division/differentiation and 




Fig. 1 Current strategies combining viral gene therapy and tissue engineering approaches for human orthopaedic 
regenerative medicine. Biomaterials may be engineered either to act as scaffolds for genetically modified cells or to behave 
as a guiding system for optimized viral gene transfer, providing in both cases a supportive environment for improved tissue 
repair.  
Tissue engineering for the delivery of genetically modified cells and tissues 
Strategies based on the seeding genetically modified cells onto scaffolds have been developed for 
implantation in sites of cartilage injury [114,115,116,117,118,119], bone defects 
[120,121,122,123,124,125,126,127,128,129,130,131,132], and tendon/ligament lesions [133, 134]. 
 
Specifically, MSCs (bone marrow, periosteum, adipose tissue) 
[114, 115, 117,118,119,120, 122,123,124,125,126, 128,129,130,131,132,133], articular 
chondrocytes [116], tenocytes [134], muscle cells [120, 121], and fibroblasts (skin) [127] have 
been first transduced with adenoviral [117, 119, 122, 124, 126,127,128,129,130, 132,133,134], 
retro/lentiviral [114, 115, 120, 121, 123,124,125, 131], and rAAV vectors [116, 118] to 
overexpress BMPs (BMP-2, -4, -7, -12) [114, 115, 120,121,122,123,124, 127, 130,131,132, 134], 
TGF-β [119, 130], FGF-2 [116], VEGF [128], stromal cell-derived factor 1 (SDF-1) [129], 
connective tissue growth factor (CTGF) [134], SOX9 [117], the runt-related transcription factor 2 
(Runx2/Cbfa1) [125, 126], Mohawk homeobox (MKX) transcription factor [133], chondromodulin 
1 (Chm-1) [118], and sonic Hedgehog (SHH) [115]. Genetically modified cells were next seeded 
in scaffolds based on polyglycolic acid (PGA) [114, 115, 117], polycaprolactone (PCL) [125], 
polylactic acid (PLA)/PCL [126], poly(DL-lactic-co-glycolic acid)/tricalcium phosphate 
(PLGA/TCP) [128], chitosan/poly(vinyl alcohol) (CS/PVA) [119], and type-I collagen (matrix, 
sponge, carrier) [116, 118, 120,121,122,123,124, 129,130,131,132,133], or encapsulated in a 
poly(ethylene glycol) diacrylate (PEGDA) hydrogel [127] or matrigel [134]. The systems were 
next implanted in sites of tissue injury, leading for instance to cartilage repair in osteochondral 
defects in rabbits for 26 weeks [115], to bone healing in rats for 1 year [127], and to tendon repair 
in rats for 8 weeks [134]. 
Tissue engineering for the delivery of viral gene vectors 
As such approaches remain complex and invasive, strategies based on scaffold-guided viral gene 
transfer may provide more convenient procedures to offer off-the-shelf therapeutic systems 
adapted for orthopaedic regenerative medicine, a concept initially employed to deliver nonviral 
vectors in their targets [19, 135,136,137,138]. Immobilization or encapsulation of viral gene 
vectors in adapted biomaterials may thus allow for a controlled release of the vehicles while 
protecting them from deleterious host responses [139,140,141,142,143,144,145,146,147]. 
 
Scaffold-guided viral gene transfer for the goal of cartilage repair has been attempted using both 
hydrogel and micellar systems (alginate, poloxamer PF68 and poloxamine T908 polymeric 
micelles based on poly(ethylene oxide)—PEO—and poly(propylene oxide)—PPO—tri-block 
copolymers, self-assembling RAD16-I peptide hydrogels, polypseudorotaxane gels) 
[148,149,150,151,152,153,154] and solid scaffolds (PCL) [155,156,157,158] carrying lentiviral 
[155,156,157,158] and rAAV vectors [148,149,150,151,152,153,154] (Table 3). Such systems 
were employed to overexpress TGF-β [153, 155], an IL-1Ra [156,157,158], and SOX9 [149, 154] 
as a means to safely target hMSCs [148,149,150, 152] and enhance their potential for 
chondrogenesis and immunomodulation [155, 156], to remodel experimental models of cartilage 
defects in situ [151, 153, 154], and to permit biological joint preservation and resurfacing 
[157, 158]. 
  
Table 3 Scaffold-guided approaches for viral gene transfer in orthopaedic regenerative medicine 
Applications Vectors Scaffolds Genes Effects References 










hMSC targeting [150] 







protection from NAbs 
[149] 
   lacZ Targeting of cartilage defects 
in situ, protection from NAbs 
[151] 
   TGF-β Remodeling of cartilage 
defects in situ 
[153] 
   SOX9  [154] 
  Alginate, 
alginate/poloxamers 
lacZ hMSC targeting [148] 
  Polypseudorotaxane gels   [152] 
 Lentiviral 
vectors 
PCL TGF-β hMSC chondrogenesis [155] 
   IL-1Ra hMSC chondrogenesis and 
immunomodulation 
[156] 
    Joint preservation and 
resurfacing 
[157, 158] 
Bone healing Adenoviral 
vectors 
β-TCP Runx2 Bone formation (rats) [159] 
 rAAV 
vectors 
β-TCP, hydroxyapatite, Ti BMP-2  [160] 
  PCL   [161] 
  PLLA  Bone formation (mice) [162] 
      
 
rAAV, recombinant adeno-associated virus vector, RAD16-I, (RADA)4 peptide, HA, hyaluronic acid, PCL, poly-ε-
caprolactone, β-TCP, β-tricalcium phosphate, Ti, titanium, PLLA, poly-L-lactide acid, lacZ, E. coli β-galactosidase, RFP, 
red fluorescent protein, SOX9, sex determining region Y-box 9, TGF-β, transforming growth factor beta, IL-1Ra, 
interleukin 1 receptor antagonist, Runx2, runt-related transcription factor 2, BMP-2, bone morphogenetic protein 2, hMSC, 
human mesenchymal stem cell, Nabs, neutralizing antibodies 
Similar approaches have been reported for bone healing strategies upon delivery of adenoviral 
[159] and rAAV vectors [160,161,162] coated on solid scaffolds (β-TCP, PCL, poly-L-lactide 
acid—PLLA) [159,160,161,162] to overexpress and BMP-2 [160,161,162] and Runx2/Cbfa1 
[159] as a means to promote bone formation and healing in bone defects like for 12 weeks in rats 
[161] (Table 3). 
 
Thus far, there is no report available showing the benefits of such a strategy for meniscal repair 
although those were discussed in a recent review of the literature [18]. Regarding the treatment of 
injured tendons and ligaments, again only a study cited the potential application of scaffold-guided 
gene transfer for tendon regeneration but using a nonviral vector [137]. 
  
Conclusions and perspectives 
Gene therapy combined with tissue engineering procedures for the controlled delivery of viral 
gene vectors is a relatively novel but very promising and achievable field of research for the goal 
of orthopaedic regenerative medicine. Indeed, as stated by Evans et al. [163] “arthritis gene 
therapy is becoming a reality”, a therapeutic concept supported by the growing body of clinical 
trials in orthopaedics [164, 165] and for the treatment of a wide spectrum of human disorders 
(monogenic, infectious, cardiovascular, neurological, ocular, and inflammatory diseases, cancer) 
[166]. With the current use of a variety of biocompatible materials well suited for orthopaedic 
applications [107], scaffold-guided viral gene transfer may offer off-the-shelf compounds capable 
of both enhancing the repair of injured orthopaedic tissues while overcoming the remaining 
barriers to effective viral gene therapy. Interestingly, the first case of gene-activated treatment has 
been successfully reported by Bozo et al. [167] who employed a collagen-hydroxyapatite sponge 
coated with a nonviral vector coding for VEGF as a bone substitute to enhance the healing of a 
mandible bone defect in a patient, overall supporting the concept for translation in orthopaedic 
patients using viral gene constructs. Nevertheless, additional work is needed in preclinical models 
to define the optimal viral vector, gene, and scaffold combination in vivo prior to receive 
regulatory approval and testing in patients. Also, the novel three-dimensional bioprinting 
technology may further provide strong tools for the one-step fabrication of scaffold-vector 
composites mimicking the structural features of a specific injured tissue [168,169,170]. Finally, it 
remains to be seen whether genome editing approaches to directly modulate the host DNA [171] 
may be also combined with scaffold-guided strategies for orthopaedic applications [172, 173] or 
whether the use of exosomes may provide additional benefits to gene- and tissue engineering-
based concepts [174]. Overall, such approaches have the potential to find their way in the clinics to 
treat patients with orthopaedic injuries in a close future. 
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